CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 146 enrolled
Drug / intervention
ticagrelor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01118325
NCT01118325Phase 2Completed

A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patients With Stable Coronary Artery Disease

AstraZeneca·interventional·Posted May 6, 2010·Updated Jul 8, 2014

In Brief

A Phase 2 clinical trial evaluating ticagrelor and clopidogrel for Stable Coronary Artery Disease. Completed, enrolled 146 participants across 13 sites in 2 countries.

Detailed Summary

The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan, Philippines
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 6, 2010
Enrollment StartApr 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.2 years ago

Interventions

ticagrelordrug

Drug oral treatment

clopidogreldrug

Drug oral treatment